60 Degrees Pharmaceuticals Announces 2025 Annual Results
Rhea-AI Summary
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported FY2025 results on March 31, 2026, with net product revenues up 65% to $1.005 million and gross profit of ~$223.8k. Operating expenses fell to ~$8.4 million, and net loss improved to ~$7.37 million. The company raised ~$4.03 million via its ATM, exhausting current shelf capacity.
Clinical and commercial progress included expanded access cures for relapsing babesiosis, pharmacy partnerships with GoodRx and Runway Health, a Phase 2 site opening, and a Yale tafenoquine license.
Positive
- Net product revenue +65% to $1.005M in FY2025
- Operating expenses down ~16% from $10.0M to $8.4M
- Gross profit stable at ~$223.8k despite write-offs
- Expanded commercial reach via GoodRx partnership to 70,000+ pharmacies
- Clinical progress with Phase 2 central site open at Mount Sinai
Negative
- Net loss of ~$7.37M in FY2025
- ATM sales of ~$4.03M exhausted shelf capacity, implying dilution
- Inventory write-offs related to a short-dated batch (non-recurring)
- Decrease in favorable derivative change reduced results by ~$1.4M
Key Figures
Market Reality Check
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-03-18 | Regulatory filing | Positive | -5.2% | Filed NDIN with FDA for Australian Chestnut Extract and related licensing steps. |
| 2026-03-11 | Clinical trial data | Positive | +84.2% | Reported all patients cured in expanded-use tafenoquine trial for relapsing babesiosis. |
| 2026-02-02 | Access partnership | Positive | +1.6% | GoodRx partnership to offer savings on ARAKODA and broaden pharmacy reach. |
| 2026-01-28 | License option | Positive | -2.9% | Exercised FSU license option for large-scale purification of castanospermine. |
| 2026-01-22 | Commercial partnership | Positive | +70.6% | Runway Health partnership to provide travelers access to ARAKODA for malaria prevention. |
News has produced mixed reactions: some partnership and clinical updates led to strong gains, while other positive developments saw selling pressure.
Over the last several months, 60 Degrees Pharmaceuticals issued multiple updates spanning partnerships, regulatory steps, and clinical data. A March 2026 clinical-trial update reporting all patients cured in an expanded-use tafenoquine study saw a sharp +84.21% move. Commercial partnerships with Runway Health and GoodRx in early 2026 also coincided with gains of +70.57% and +1.57%, respectively. By contrast, regulatory and licensing news in January and March 2026 triggered modest declines. Against this backdrop, the current annual results combine revenue growth with continued losses.
Market Pulse Summary
This announcement combines strong top-line momentum—net product revenues rising 65% to $1,005,000—with persistent losses, including a $7.37 million net loss and $8.4 million in operating expenses. Management highlights multiple commercial partnerships, clinical progress in babesiosis, and expanded access initiatives, supported by $4,026,722 raised via an ATM facility. Investors may watch upcoming Phase 2 data, revenue trajectory, and expense discipline to assess whether growth can materially narrow losses over time.
Key Terms
atm facility financial
expanded access study medical
phase 2 medical
sponsored research agreement financial
patent license agreement regulatory
AI-generated analysis. Not financial advice.
- FY 2025 net product revenues increased
65% to$1,005,000 - Current shelf capacity exhausted after raise of
$4 million through an ATM facility
WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025.
Financial Highlights for the Fiscal Year Ended December 31, 2025:
- Net product revenues increased
65% from$607.6 thousand in 2024 to$1.0 million in 2025, driven by rising sales, price increases, and fewer returns. - The Company achieved a gross profit of approximately
$223.8 thousand in 2025, compared with approximately$222.8 thousand in 2024. Gross profit remained relatively stable despite inventory write-offs associated with a final batch of short-dated product entering the supply chain. This charge was a necessary, non-recurring cost incurred as part of scaling operations. - Operating expenses were approximately
$8.4 million in 2025, compared with approximately$10.0 million in 2024. The decrease in Research and Development costs of$2.9 million was due to 2024 including$3.2 million of non-cash and non-recurring charges. The increase in general and administrative expenses of$1.3 million was driven primarily by$967.6 thousand in additional sales advisory, advertising and promotion expenses. - Net loss attributable to common shareholders in 2025 was approximately
$7.37 million , or$11.73 per share, compared with a net loss of approximately$7.96 million , or$74.17 per share, in 2024 — an improvement of approximately$590 thousand . This improvement was driven primarily by the absence of non-recurring, non-cash Research and Development charges that burdened fiscal year 2024, partially offset by higher selling expenses in fiscal year 2025 and a$1.4 million reduction in the favorable Change in Fair Value of Derivative Liabilities.
Recent Business Highlights:
- As of March 30, 2026, the Company had 2,636,788 shares outstanding. In the 12 months through March 27, 2026 the Company had offered and sold approximately
$4,026,722 in common shares using its At-the-Market facility, exhausting current baby shelf capacity. - In March 2026, the Company announced that all patients enrolled in its expanded access study for relapsing babesiosis were cured after tafenoquine-based treatment and called for treatment guidelines to be reviewed in light of the new data. The Company believes that the next clinical data release, the interim analysis of its randomized hospital study, could occur as early as late September if recruitment patterns of the 2026 tick season mirror those of the 2025 season.
- In February 2026, the Company partnered with GoodRx to provide eligible consumers savings of up to
30% on ARAKODA®, expanding sales footprint to more than 70,000 pharmacies nationwide. - In January 2026, the Company partnered with Runway Health to expand sales of ARAKODA® for malaria prevention through a travel-focused telehealth platform.
- In January 2026, the Company exercised its Florida State University license option for large-scale purification of castanospermine and signaled readiness to commence the regulatory process for Australian Chestnut Extract as a non-prescription botanical product.
- In November 2025, the central study site at Mount Sinai opened for patient enrollment in the Phase 2 B-FREE Chronic Babesiosis Study, which is designed to run about 12 months and enroll up to 100 patients.
- In July 2025, the Company entered into a sponsored research agreement with Tulane University to evaluate tafenoquine activity against Borrelia (Lyme) and Bartonella bacteria.
- In April 2025, the Company announced a patent license agreement with Yale School of Medicine and Yale School of Public Health to jointly advance the development and commercialization of tafenoquine for babesiosis treatment and prevention.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors, including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators, future regulations, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen), Australian Chestnut Extract or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666
FAQ
How much did 60 Degrees Pharmaceuticals (SXTP) revenue grow in FY2025?
Did 60 Degrees Pharmaceuticals (SXTP) raise capital in 2026 and what was the amount?
What commercial partnerships did 60 Degrees Pharmaceuticals (SXTP) announce in early 2026?
What clinical updates did 60 Degrees Pharmaceuticals (SXTP) provide about babesiosis studies?
How did operating expenses and gross profit change for 60 Degrees Pharmaceuticals (SXTP) in 2025?
